Four Prednisone Bursts a Year and the Bone Density Scan That Finally Moved
A man treated for years with prednisone bursts for recurring asthma and sinus flares — never continuously, always tapered off — finally shows real bone loss on his first-ever DEXA, testing exactly when accumulated intermittent exposure crosses the threshold that continuous dosing crosses more visibly.
Arthur M., 69, retired four years ago from a career restoring antique furniture, work he still does on a smaller scale in his garage for friends and neighbors who ask. Severe eosinophilic asthma with chronic rhinosinusitis and nasal polyps has shaped much of the last decade of his life — not constantly, but in recurring flares, roughly four times a year, each treated with a two-week prednisone burst (40mg tapering over ten to fourteen days) that reliably brings him back to baseline within days. He has never been on continuous daily steroids, and until this visit had never had a bone density scan, on the reasoning — his own and, until recently, his pulmonologist's — that intermittent bursts weren't the same exposure that triggers routine osteoporosis screening.
His first DEXA, ordered this year mostly as a baseline given his age, showed a hip T-score of -2.3 — osteopenia bordering on osteoporotic range, real bone loss with no other obvious explanation once vitamin D deficiency and secondary causes were checked and ruled out. Simple arithmetic on his burst history is less reassuring than it first looks. A 40mg course tapered over ten to fourteen days delivers on the order of 250 to 300mg of prednisone; twenty-four such bursts across six years put his cumulative exposure somewhere between 6,000 and 7,000mg, which flattened across those years comes to roughly 2.7mg a day — just above the 2.5mg daily figure at which the glucocorticoid-induced osteoporosis guideline begins treating a patient as chronically exposed at all. Spreading the total evenly is still the wrong way to read a pattern of repeated short, high peaks rather than one steady low level; the point is that even the flattened version no longer places him outside the guideline's own definition.
Arthur has never thought of himself as someone on chronic steroids — each burst felt, at the time, like a discrete, temporary fix for a discrete, temporary flare, and the gaps between them, sometimes four or five months of feeling entirely normal, reinforced that sense of the drug as an occasional tool rather than an ongoing exposure. The DEXA result landed as a genuine surprise, and he has asked, reasonably, whether anyone should have been tracking this all along rather than waiting for a baseline scan he happened to get at 69 simply because of his age, not because of the treatment pattern that may have actually caused it.
What four bursts a year actually add up to
I'd treat this scan as the trigger it is, independent of how his burst pattern technically maps onto the ACR glucocorticoid-induced osteoporosis guideline's cumulative-dose categories. A hip T-score of -2.3 in a 69-year-old man with no other identified cause is real bone loss happening in front of us, and I'd start bisphosphonate therapy and calcium/vitamin D optimization now rather than wait for a worse follow-up scan to confirm what this one is already showing.
I want to name something about the guideline itself before we lean on it further: the ACR risk-stratification thresholds were derived from and validated in continuous daily-dosing cohorts — patients on 5 or 7.5mg every day, not patients taking 40mg for two weeks four times a year. Each burst produces a sharp glucocorticoid receptor activation that his body then has to recover from before the next one starts, and there's real pharmacologic reason to think that pattern isn't equivalent, dose-for-dose, to the same total spread evenly across the year.
I'm not disputing the endocrinologist's read of the scan — I'm cautioning against the arithmetic clinicians tend to reach for here, which undercounts what a tapered burst actually delivers and then concludes the total is unremarkable. Run properly it lands near six or seven thousand milligrams, which even flattened across six years sits above the daily figure the guideline uses to define chronic exposure in the first place. And the guideline still wasn't built for his pattern.
The piece I'd add is that bone density is only the finding we happened to measure — the same burst pattern that produced this DEXA result has also been quietly accumulating adrenal-axis and metabolic cost we haven't specifically screened for, and it will keep doing so with every future flare unless something changes upstream. Mepolizumab has real trial evidence (the MENSA and SIRIUS trials) showing meaningful reduction in exacerbation frequency and oral steroid burden specifically in eosinophilic asthma like his — his eosinophil count qualifies him directly. Treating the bone and starting the biologic aren't competing choices; they're addressing two different links in the same chain.
Agreed: start mepolizumab to address the underlying exacerbation frequency, begin alendronate and optimized calcium/vitamin D for the confirmed bone loss, and add HPA-axis screening that should arguably have been done years earlier given the burst pattern.
The pharmacologist's caution about the ACR guideline's fit to intermittent dosing was noted as a real, unresolved gap in the evidence base rather than something this visit could settle — all three agreed Arthur's case is a useful example of exactly the pattern that guideline may be under-serving, worth flagging in his chart for whoever manages his bone health going forward.